The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | Targeting DNA methylation as a therapeutic target in multiple myeloma
Epigenetic modifications, such as DNA methylation, can lead to or complicate disease, and lead to worse patient outcomes. Speaking from the Myeloma 2017 meeting in Edinburgh, UK, Benjamin Barwick, PhD, of Emory University, Atlanta, GA, outlines how these alterations could be explored in terms of targeting them for multiple myeloma (MM) therapies. Dr Barwick highlights the potential to perform clinical trials for MM treatment with approved drugs that target DNA methylation in myelodysplastic syndromes and leukemia.
